Grazax

01/01/2012 - "261 patients with grass allergy were enrolled and randomized (1 : 1) to 1-year treatment with AIT (Grazax) using a CED (group A; n = 122) or without (Group B, n = 139). "
11/01/2007 - "(5) If Grazax becomes widely prescribed and is covered by provincial drug plans, the costs to the Canadian health care system and the impact on allergy specialist services could be substantial."
11/01/2007 - "(4) Adverse effects of Grazax are generally mild to moderate local allergic reactions of short duration, and include itching and swelling of the mouth, and throat irritation. "
01/01/2010 - "The fast-dissolving grass allergy immunotherapy tablet (grass AIT), Grazax, has proven effective in grass pollen-induced rhinoconjunctivitis. "
01/01/2015 - "This is a randomized, double-blind, single-centre, placebo controlled, two arm time course study based in the United Kingdom comparing sublingual allergy immunotherapy tablet (GRAZAX(®), ALK-Abello Horsholm, Denmark) plus standard treatment with placebo plus standard treatment. "

01/01/2012 - "Since this type of sensitization is more common in Mediterranean countries than in countries where most patients were enrolled in clinical trials on GRAZAX (Phleum pratense 75,000 SQ-T/2, 800 BAU, ALK), the aim of this study was to analyze tolerability to GRAZAX under clinical practice conditions in patients with grass pollen allergy. "
12/01/2007 - "In randomized double-blind placebo controlled trials Grazax reduces symptoms and medication scores in adults with hay fever. "
11/01/2007 - "(2) Evidence from three randomized controlled trials indicates modest improvements in hay fever symptoms, with reduced use of medication to control symptoms (rescue medication use) in adults who took Grazax compared with placebo. "
05/01/2010 - "Here we assess the latest evidence for Grazax and reconsider the drug's place in the management of patients with hay fever."
05/01/2010 - "Grazax for hay fever--what's new?"

12/01/2008 - "Subjects treated with Grazax also had an increased number of well days and improved quality of life, and more subjects experienced excellent rhino-conjunctivitis control. "
01/01/2011 - "Grazax is indicated for treatment of grass pollen-induced rhinitis and conjunctivitis in adult and pediatric patients. "
12/01/2008 - "We conclude that Grazax is efficacious and safe for treatment of rhino-conjunctivitis due to grass pollen allergy."
12/01/2008 - "Grazax is indicated for treatment of grass pollen-induced rhinitis and conjunctivitis in adult patients with clinically relevant symptoms and diagnosed with a positive skin prick test and/or specific IgE test to grass pollen. "
05/01/2010 - "In 2008, we reviewed Grazax, a sublingual tablet containing standardised allergen extract of grass pollen.1 At the time, this product was licensed for the treatment of adults with proven grass-pollen-induced rhinitis and conjunctivitis (hay fever). "

08/01/2007 - "Grazax has effects on multiple allergic symptoms, including nasal blockage, and is an effective treatment of rhinoconjunctivitis, thereby reducing the need for topical anti-allergic drugs."

10/01/2011 - "The objective of this publication is to describe the rationale behind the design of and report on the recruitment for the ongoing pediatric Grazax Asthma Prevention (GAP) trial. "
12/01/2008 - "SIT with Grazax is a cost-effective strategy compared with standard management of patients with rhinoconjunctivitis and co-existing asthma."
12/01/2008 - "To assess the cost-effectiveness of Grazax in patients with rhinoconjunctivitis and co-existing asthma. "
12/01/2008 - "Grazax--the first tablet-based SIT--is indicated for the treatment of patients with grass pollen-induced rhinoconjunctivitis, including those with co-existing asthma. "
12/01/2008 - "Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma."